Cargando…

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome

Pump-guided intrajejunal levodopa administration is one of the indispensable forms of therapy in advanced Parkinson's syndrome, along with deep brain stimulation and subcutaneous apomorphine injection. The standard application of levodopa gel via a JET-PEG, i.e. a percutaneous endoscopic gastro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grund, K. E., Zipfel, A., Duckworth-Mothes, B., Jost, W. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645636/ https://www.ncbi.nlm.nih.gov/pubmed/36809488 http://dx.doi.org/10.1007/s00702-023-02601-0

Ejemplares similares

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
por: Jost, Wolfgang H.
Publicado: (2023)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Effects of Levodopa on Impairments to High-Level Vision in Parkinson's Disease
por: Anderson, Stephen, et al.
Publicado: (2020)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease
por: Zham, Poonam, et al.
Publicado: (2021)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Case report: Levodopa-responsive parkinsonism with akinetic mutism after ventriculo-peritoneal shunt
por: Zhang, Ying, et al.
Publicado: (2023)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease
por: Nasir, Usama, et al.
Publicado: (2018)

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease
por: Li, Lanting, et al.
Publicado: (2020)

Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study
por: Popa, Luminita C., et al.
Publicado: (2020)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design
por: Brodell, David W, et al.
Publicado: (2012)

Anxiety and Levodopa Equivalent Daily Dose Are Potential Predictors of Sleep Quality in Patients With Parkinson Disease in Taiwan
por: Chang, Chun-Wei, et al.
Publicado: (2019)

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
por: Aljuaid, Maram, et al.
Publicado: (2019)

Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
por: Jeong, Eun Hye, et al.
Publicado: (2018)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Wu, Yi, et al.
Publicado: (2021)

Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease
por: Li, Jiping, et al.
Publicado: (2021)

Neuropathological features of levodopa-responsive parkinsonism in multiple system atrophy: an autopsy case report and comparative neuropathological study
por: Tamura, Mitsuyoshi, et al.
Publicado: (2023)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2017)

The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report
por: Thirunavukarasu, Suresh, et al.
Publicado: (2023)

The Relationship Between Electrical Energy Delivered by Deep Brain Stimulation and Levodopa-Induced Dyskinesias in Parkinson's Disease: A Retrospective Preliminary Analysis
por: Prenassi, Marco, et al.
Publicado: (2021)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

A review of studies on gut microbiota and levodopa metabolism
por: Zhong, Zhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7n0mtlatubr59mv18orera0nsf